Apostolou Panagiotis, Toloudi Maria, Kourtidou Eleni, Mimikakou Georgia, Vlachou Ioanna, Chatziioannou Marina, Papasotiriou Ioannis
Research Genetic Cancer Centre Ltd (R.G.C.C. Ltd), Filotas, Florina Greece.
J Biol Res (Thessalon). 2014 Aug 1;21(1):14. doi: 10.1186/2241-5793-21-14. eCollection 2014 Dec.
Determination of response to chemotherapy is a major requirement of personalized medicine. Resistance, whether developed or native, critically affects a treatment's success. Single Cell Gel lectrophoresis - also known as a comet assay - is used to detect DNA damage at the level of individual eukaryotic cells. We assessed the use of comet assays in determining response to chemotherapeutic drugs that are widely used in breast and colon cancer.
We treated human breast and colon cancer cell lines with melphalan, cisplatin, mechlorethamine or doxorubicin, as monotherapies. Drug activities varied even in the same cancer types, further demonstrating the heterogeneity of different cancer types.
The comet assay technique can provide reliable and quick results with minimum requirements and is applicable to a wide variety of drugs.
确定化疗反应是个性化医疗的一项主要要求。耐药性，无论是后天产生的还是天然存在的，都严重影响治疗的成功与否。单细胞凝胶电泳——也称为彗星试验——用于在单个真核细胞水平上检测DNA损伤。我们评估了彗星试验在确定乳腺癌和结肠癌中广泛使用的化疗药物反应方面的应用。
我们用美法仑、顺铂、氮芥或阿霉素作为单一疗法处理人乳腺癌和结肠癌细胞系。即使在相同的癌症类型中，药物活性也有所不同，进一步证明了不同癌症类型的异质性。
彗星试验技术能够以最低的要求提供可靠且快速的结果，并且适用于多种药物。
